enVVeno director sells 11 shares for about $123

A director of enVVeno Medical Corp reported a small Rule 10b5-1 plan sale and continues to hold 2,351 shares directly.

Rhea-AI Filing Summary

enVVeno Medical Corp (NVNO) director Francis Duhay reported selling 11 shares of common stock on September 11, 2026 at a reported price of $11.21 per share in an open-market or private transaction. The sale was completed pursuant to a Rule 10b5-1 trading plan adopted in June 2025, and he directly holds 2,351 shares after the transaction.

Insider Trade Summary 10b5-1

Net Seller: 11 shares

Net Sell 1 txn

Insider Duhay Francis

Role Director

Sold 11 shs ($123.31)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	11	$11.21	$123.31

Holdings After Transaction: Common Stock — 2,351 shares (Direct)

Footnotes (1)

1. F1. This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

Key Figures

Shares sold: 11 shares Sale price per share: $11.21 per share Transaction value: $123.31 +1 more

4 metrics

Shares sold 11 shares Common stock sale reported for September 11, 2026

Sale price per share $11.21 per share Reported price for the September 11, 2026 sale

Transaction value $123.31 11 shares sold at $11.21 per share

Shares held after transaction 2,351 shares Direct ownership by Francis Duhay after the sale

Key Terms

Rule 10b5-1 trading plan

1 terms

Rule 10b5-1 trading plan regulatory

"This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NVNO report for director Francis Duhay?

Director Francis Duhay reported a sale of 11 shares of enVVeno Medical Corp common stock on September 11, 2026, executed as an open-market or private transaction at a reported price of $11.21 per share.

How many enVVeno Medical Corp (NVNO) shares does Francis Duhay hold after this sale?

After the reported transaction, Francis Duhay directly holds 2,351 shares of enVVeno Medical Corp common stock, according to the Form 4 disclosure.

Was the NVNO insider sale by Francis Duhay under a Rule 10b5-1 plan?

Yes. A footnote states the transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by Francis Duhay in June 2025.

What was the total dollar value of the NVNO shares sold by Francis Duhay?

Based on the reported 11 shares sold at $11.21 per share, the transaction value was approximately $123.31.

Does the filing indicate any remaining derivative securities for NVNO held by Francis Duhay?

No remaining derivative positions are listed in this Form 4; only the common stock sale of 11 shares and the 2,351 shares held directly after the transaction are reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:57 PM Accepted by SEC EDGAR 09/14/2026 - 06:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duhay Francis

(Last) (First) (Middle)

C/O ENVVENO MEDICAL CORPORATION,

70 DOPPLER

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
enVVeno Medical Corp [ NVNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S(1)		11	D	$11.21	2,351	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

	/s/ Francis Duhay	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)